Recent studies in The Journal of Nuclear Medicine have introduced new imaging techniques, including PET-based methods, to improve cancer diagnosis and treatment. Additionally, an open-source pipeline has been developed to automate tumor segmentation, and a new imaging approach has been shown to visualize therapeutic radionuclides.
Recent studies published in The Journal of Nuclear Medicine have investigated new treatments for liver fibrosis, thyroid cancer, and prostate cancer, including the use of PET tracers and radioactive iodine therapy. These studies have shown promising results, including improved imaging and biochemical responses, and increased radiation ...
New research in nuclear medicine advances detection and treatment of clear cell renal cell carcinoma with high accuracy, while SSTR antagonists show potential for imaging and treatment of neuroendocrine tumors. Alternative beta-emitting radionuclides are also being explored for targeted radiopharmaceutical therapy.
A new radiotracer, 18F-FDG PET/CT, has been shown to be highly effective in detecting rare and aggressive kidney cancer, renal medullary carcinoma (RMC). The tracer identified lesions in 98% of RMC patients and led to a change in treatment plan for 21% of patients with active disease, highlighting its potential to improve patient care.
Several new nuclear medicine approaches are being developed and evaluated for their potential to improve cancer imaging and treatment. Researchers have made significant progress in targeting specific markers and molecules in cancer cells, including CD163, CEACAM5, and DLL3. These advancements offer promising avenues for developing more...
A new study found that combining PET/MRI findings with EEG results and a structured presurgical evaluation improved the identification of seizure-causing brain tissue in pediatric epilepsy patients. 76 percent of patients who underwent surgery were free from seizures after two years of follow-up.
Researchers developed V-UNet, a novel model combining global and local information to address noise and redundant information in medical images. The model achieved competitive segmentation performance while maintaining low computational requirements, promising a more efficient and robust AI-assisted medical image analysis.
A new PET/MRI technique targeting fibroblast activation protein (FAP) overexpressed in endometriosis accurately maps the extent of the disease, enabling personalized management and improving patient outcomes. The approach was particularly effective in regions of the pelvis and abdomen that are typically difficult to image.
The new imaging system allows scientists to capture high-resolution fluorescence images in real time under normal room lighting, giving them a more complete picture of biological changes. SphynxVision can capture multiple images per second and reveal remarkably small details, such as tiny blood vessels and clusters of cancer cells.
Researchers developed a dual-threshold approach for measuring tumor volume on PET/CT, showing higher total lesion volume associated with shorter overall survival and time to treatment failure. FAPI PET/CT improved detection of ovarian cancer spread, while CD8-targeted PET tracked immune response in lung cancer.
PSMA PET/CT detected recurrent prostate cancer after minimally invasive treatments and identified malignant peripheral nerve sheath tumors with high accuracy. Researchers also found varying access to PSMA-targeted theranostics between Brazil and Europe.
Research published in The Journal of Nuclear Medicine highlights the importance of intermediate amyloid PET uptake in Alzheimer's disease diagnosis and its association with cognitive decline. Additionally, studies show promising results for early SPECT/CT response prediction in PSMA-positive prostate cancer treatment, as well as potent...
New research articles published in The Journal of Nuclear Medicine explore intensified PSMA-targeted therapy for advanced prostate cancer, as well as novel approaches to targeted radiopharmaceutical therapy. Studies also investigate radiation doses from PSMA-targeted therapy and their relationship with treatment outcomes, while others ...
Dr. Natalie Lui and her team are developing a molecular imaging agent, pan800, to identify lung cancer tumors during surgery. This technique aims to reduce complications and recurrence by enabling surgeons to achieve complete removal of tumors.
Physicists have developed a method to visualize three-dimensional wavefunctions of molecules, enabling the study of molecular interactions. The technique, which uses a table-top soft-X-ray laser and powerful computer algorithms, allows for the imaging of features smaller than atomic scales.
A new study published in The Journal of Nuclear Medicine has found that dual-energy SPECT may enable faster monitoring of PSMA therapy, reducing imaging time from 18 minutes to 9 minutes. Another study showed a prognostic model using PSMA PET can predict outcomes after therapy, including overall survival and PSA progression-free survival.
Researchers found that high brain metabolism is associated with longer overall survival, and it's an independent prognostic factor for overall survival. Brain metabolism measured by ¹⁸F-FDG PET/CT provides valuable insight into patient outcomes and may help identify patients most likely to benefit from early supportive care.
A new study found that PET/CT scans improved the diagnosis of fever of unknown origin (FUO) in nearly 75% of patients. The study identified predictive markers for a positive scan, including high C-reactive protein and short duration of prior antibiotic therapy.
Researchers have made significant breakthroughs in targeted radiation therapy for pancreatic cancer, PARP inhibitor treatment, and Alzheimer's disease detection. New PET-based scores may predict prostate cancer outcomes, while blood cell mutations are associated with side effects in advanced prostate cancer patients.
Recent studies published in The Journal of Nuclear Medicine have shown that combining multiparametric MRI with PET improves the detection of clinically significant prostate cancer. Additionally, PSMA PET/CT-guided biopsies have been found to detect more significant cancers than standard biopsies.
A second PSMA PET scan changed treatment plans for nearly half of patients whose first scan was negative, detecting evidence of disease in 56% of cases. The study found that repeat imaging was most likely to detect disease in patients with higher PSA levels and a PSA doubling time of less than twelve months.
The Journal of Nuclear Medicine (JNM) has increased its impact factor from 9.1 to 9.6, ranking eighth overall among medical imaging journals. The journal saw a nearly 10% increase in citations and improved performance in various categories.
Researchers evaluated two somatostatin receptor PET tracers for breast cancer treatment, found SSTR-positive tumors in many estrogen receptor-positive cases. A new PET tracer showed promise for detecting Staph infections, while an interim PET scan may help track response to PSMA therapy in advanced prostate cancer.
Mary Beth Farrell has been honored with the 2026 SNMMI-TS Lifetime Achievement Award for her decades-long dedication to elevating the nuclear medicine profession. Her leadership in accreditation, research, and education has shaped national standards and driven quality improvement initiatives that continue to impact patient care.
A novel FAP-targeted radiopharmaceutical therapy approach has shown safety and effectiveness in treating various types of cancer, including breast, colorectal, gastric, and ovarian cancers. The treatment achieved objective responses in approximately two-thirds of patients and disease control in over 80%.
Research on targeted radioactive gold nanoparticles shows promise against aggressive brain tumors. Ultra-high-resolution PET scanners provide detailed views of mouse brains. New imaging tracers target key drivers of prostate cancer growth.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced the recipients of five Drs. Jane & Abass Alavi Mars Shot Research Awards, supporting studies on inflammatory bowel disease, artery inflammation, and other conditions.
The Journal of Nuclear Medicine has published several groundbreaking studies on targeted radiotherapy approaches for various types of cancer. Researchers have successfully identified tumors using fibroblast activation protein (FAP)-targeting compounds and explored the potential of PET/MRI scans in detecting endometriosis and recurrent ...
The SNMMI 2026 Annual Meeting showcased significant advancements in precision nuclear medicine, AI, theranostics, and molecular imaging. The meeting featured over 1,500 abstracts, a 25% increase from last year's meeting, and presented new educational sessions alongside networking opportunities.
Heather Jacene, MD, has been named president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), with a focus on strengthening the organization and advancing nuclear medicine. She plans to create new opportunities for members to participate actively in SNMMI and conduct multidisciplinary collaborations.
A new PET imaging approach measures synaptic density in the spinal cord, allowing physicians to monitor disease progression and evaluate treatment effectiveness. This technique detects widespread reductions in synaptic connections across the brain and spinal cord in patients with multiple sclerosis.
Jason Lewis, PhD, FSNMMI, has been elected as SNMMI's vice president-elect. He aims to strengthen education, scientific exchange, and outreach efforts to integrate basic scientists into SNMMI programs. Lewis holds various academic and research positions.
A new end-to-end PET imaging approach for osteosarcoma distinguishes tumor tissue from normal tissue and assesses surgical margins in real-time. The platform enables precise tumor resection, reducing the risk of local recurrence and preserving maximum limb function.
Gary Ulaner, a renowned nuclear medicine expert, has been elected president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He aims to advance SNMMI's Mars Shot initiative, expand educational activities for professionals, and increase funding for training new radiochemistry and physics specialists.
Researchers have identified RET as a biomarker for neuroendocrine prostate cancer and developed a theranostic pair for PET imaging and radioligand therapy. The approach demonstrates high uptake in tumors and shows promise for treatment, offering an alternative to current PSMA-based imaging.
A novel PET imaging framework reveals bariatric surgery induces coordinated changes in metabolic function across organs, including fat, liver, pancreas, muscle, and immune-endocrine organs. These findings support the use of whole-body PET/CT as a tool to map organ-level metabolic health.
A new PET radiotracer, 18F-GP1 PET/CT, accurately detects deep vein thrombosis in the legs and reveals lung clot migration. The approach may support faster diagnosis and improve patient care by detecting disease early.
A newly developed portable point-of-care PET technology provides high-quality results for guiding biopsies, tumor ablations, and other interventional procedures. The bedside device offers real-time visual feedback, making it a cost-effective approach for hospitals to perform procedures in constrained clinical environments.
A new PET radiotracer can effectively image overactive adrenal glands, allowing for a non-invasive approach to diagnose primary aldosteronism. This could enable physicians to tailor treatment plans for patients with this condition.
A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background contrast in detecting clear cell renal cell carcinoma (ccRCC). The tracer successfully identified additional metastatic lesions missed by standard imaging while reducing abdominal background noise.
Dr. Martin G. Pomper has been awarded the 2026 Benedict Cassen Prize for his outstanding contributions to nuclear medicine, particularly in the development of PSMA-targeted agents. His work has led to significant advances in cancer diagnosis and treatment, including the creation of commercial PSMA-targeted PET agents.
A new type of peptide receptor radionuclide therapy (PRRT) shows promise in treating metastatic neuroendocrine tumors. The novel approach resulted in partial remission in the majority of patients with advanced cases, with manageable safety and encouraging antitumor activity.
Researchers developed a novel PET imaging approach to detect immune-related adverse events in patients receiving immunotherapy. The approach uses CCR2-targeted radiotracer to visualize both tumor progression and cardiac inflammatory responses. Co-treatment with itacitinib improved tumor response while reducing cardiac inflammation.
Dr. Richard E. Carson has made significant contributions to the understanding and application of nuclear medicine, particularly in neuroscience and neuropsychiatric disorders. His work led to the development of diverse tracer kinetic modeling techniques and innovative imaging systems like NeuroEXPLORER.
A study found that a specific pattern of brain metabolism visualized with PET imaging can predict which patients are most likely to benefit from Alzheimer's disease therapy. Patients with this pattern experienced stabilized cognitive performance, while those with other patterns had significant cognitive decline.
A new SPECT/CT imaging approach can accurately differentiate between inflammation and fibrosis in interstitial lung disease (ILD) patients. Researchers used the molecular imaging agent ⁹⁹ᵐTc-maraciclatide to visualize inflammation, which is crucial for determining treatment decisions.
Johnson aims to protect and advance the scope of practice for nuclear medicine technologists, strengthening the national workforce pipeline through education-driven partnerships with industry. She will also formalize standardized training resources as new technologies are introduced.
Irène Buvat, a pioneering researcher, has received the SNMMI's George Charles de Hevesy Nuclear Pioneer Award for her groundbreaking work in molecular imaging quantification. Her contributions have led to improved diagnosis and treatment of cancer through the development of simulation and radiomics tools.
Researchers developed a new tau PET radiotracer that can accurately detect chronic traumatic encephalopathy (CTE) in living patients. The tracer's ability to bind to tau pathology was confirmed in post-mortem CTE tissue, and preliminary results suggest it could provide an early diagnostic biomarker for the disease.
PSMA PET scans have been shown to detect bone metastases that conventional imaging misses, resulting in faster disease progression and worse overall survival. Patients with these undetected lesions are at a higher risk of progressing to treatment-resistant cancer and dying sooner.
Shannon Youngblood has been elected as the new president of the SNMMI Technologist Section. She will focus on amplifying visibility through advocacy, building a more inclusive workforce through educational opportunities, and streamlining professional development to stay current with advancements in theranostics and cardiac PET-CT.
The Society of Nuclear Medicine and Molecular Imaging recognized six new Fellows for their exceptional contributions to the field. The SNMMI Fellowship honors members who have demonstrated excellence in scientific discovery, educational efforts, or clinical practice.
Vasken Dilsizian, MD, has received the Minoshima-Pappas Transformational Leadership Award for his vision and leadership in advancing nuclear medicine and molecular imaging. He has made significant contributions to the field of cardiovascular diseases through his innovative scientific work.
A new machine-learning model uses pre-therapy PET/CT scans to estimate radiation dose to tumors and healthy organs, improving patient selection and reducing toxicity risk. The study's findings suggest a promising ability to predict post-therapy dosimetry, which may optimize treatment plans for individual patients.
Researchers have made significant breakthroughs in nuclear medicine, with studies revealing uneven radiation doses in tiny kidney structures, improving survival rates for prostate cancer patients through targeted radiation therapy, and developing a new PET imaging approach to detect abdominal cancer spread. These advancements aim to im...
Recent studies published in The Journal of Nuclear Medicine investigate the safety of kidney treatments, effectiveness of radioactive iodine for dialysis patients, and the use of new PET imaging agents to detect breast cancer spread. Researchers also explored emerging techniques like FAPI PET scans for improved detection and treatment ...
Recent research published in The Journal of Nuclear Medicine has made significant advancements in brain imaging and cancer treatment. A new wearable brain imaging system, SmartBrain, enables real-time imaging beyond the lab, capturing high-resolution images of brain activity without requiring patients to remain still.
A new pretargeted radioimmunotherapy technique has been shown to be effective and safe in eradicating tumors from a preclinical colorectal cancer model. The multi-step theranostic approach delivers alpha-emitting radiation directly to tumors while limiting exposure to healthy tissues.
Scientists successfully built the smallest X-ray interferometer to measure how X-rays interact with atomic nuclei. This breakthrough technology enables precise measurement of X-ray refraction and provides new avenues for research.
Researchers have made significant breakthroughs in prostate cancer treatment with new imaging techniques and targeted therapies, including a PSMA-targeting antibody and a CD44v6-targeting radiotherapy. These advancements aim to improve patient outcomes by tailoring diagnosis and treatment to individual needs.